Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
May, 2026
May 2026
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Chokri Ben Lamine: Hematology Pearls on Portal Vein Thrombosis
AI generated
Apr 5, 2026, 15:16

Chokri Ben Lamine: Hematology Pearls on Portal Vein Thrombosis

Chokri Ben Lamine, Adult Hematology and SCT Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital and Research Center, shared a post on X:

“Portal Vein Thrombosis (PVT) – Hematology Pearls

Thrombosis of the portal vein with or without extension to the splenic vein or superior mesenteric vein leading to risk of portal hypertension

Classification

  • Acute vs chronic
  • Bland vs tumor thrombus ( HCC)

Key Risk Factors:

  • MPNs (especially JAK2 V617F positive) are the most common systemic cause
  • Thrombophilia:
  1. Factor V Leiden
  2. Prothrombin G20210A mutation
  3. Decreased Protein C and Protein S
  4. Decreased Antithrombin
  • PNH (always screen in unexplained PVT)
  • Intra-abdominal infection/inflammation (appendicitis, pancreatitis)
  • Cirrhosis / malignancy
  • OCPs, pregnancy

Pathophysiology:

Virchow triad leads to portal flow stasis and endothelial injury, and hypercoagulability

Clinical Presentation:

Acute: abdominal pain, fever, nausea, increased lactate (if bowel ischemia).

Chronic: asymptomatic progressing to splenomegaly, varices, and thrombocytopenia.

Diagnosis:

  • Doppler US is first line
  • CT in the portal venous phase is the gold standard for assessing the extent of disease and for detecting bowel ischemia.
  • Workup ALL non-cirrhotic:
  1. JAK2 positive or negative, CALR or MPL
  2. PNH flow cytometry
  3. Thrombophilia panel (selective, timing matters)

 Red Flags 

  • Bowel ischemia leads to urgent anticoagulation and surgery
  • Tumor thrombus leads to no anticoagulation alone (treat malignancy).

Management (Guideline-based):

  • Anticoagulation is the cornerstone.
  • LMWH changes to DOAC or VKA (individualized).
  • Duration is three to six months or more.
  • Indefinite if there is MPN or it is unprovoked.

Cirrhosis:

  • Anticoag SAFE if no active bleeding (AASLD/EASL)
  • Improves recanalization

Interventions:

  • TIPS is indicated for refractory portal hypertension or disease progression.
  • Thrombolysis is used in selected acute severe cases.

Monitoring:

  • Imaging at three months shows recanalization.
  • Platelets decreased, consider hypersplenism or MPN evolution.

Special Hematology Points:

  • Always screen JAK2 in splanchnic thrombosis EVEN with normal CBC
  • PNH clone is treated with Eculizumab or Ravulizumab.
  • MPN-associated cases require adding cytoreduction, for example, with hydroxyurea.

Prognosis:

  • Recanalization if early anticoag
  • Chronic cases lead to portal cavernoma and lifelong complications.

Key Studies:

  • AASLD 2020 guidance (vascular liver disorders)
  • EASL 2016 PVT guidelines
  • DeLeve LD et al., Hepatology.”

Stay updated with Hemostasis Today.

 

 

 

Chokri Ben Lamine Health Hematology Hemophilia Hemostasis Hemostasis News Hemostasis Today JAK2 Medicine portal vein thrombosis vascular liver disorders
NewsFeed